3 Biotech Stocks That Could Double in 2022
Here's why they picked Adicet Bio (NASDAQ: ACET), ChemoCentryx (NASDAQ: CCXI), and NRx Pharmaceuticals (NASDAQ: NRXP). ChemoCentryx launched the drug shortly after receiving approval in the U.S. Tavneos is also approved for use in Japan.